ANAB

AnaptysBio, Inc. (ANAB) | Rumor.io

AnaptysBio

ANAB

Attention (50-day avg)0%

Attention rank (50-day avg)#2,276

Bullish sentiment (50-day avg)100%

Price to earnings ratio-110.5

Market capitalization1.5B

Earnings per share-1.02

Dividend yield (TTM)—

Revenue (annual)234.6M

Net income (annual)-13.2M

Social

What share of all stock conversation is about ANAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Apr 27

AnaptysBio's shares are trading higher after a Delaware Chancery Court ruled in favor of the company in a breach of contract claim, leaving current royalty rates intact.
The company's restructuring into a royalty management firm, following the spin-off of First Tracks Biotherapeutics, has received a positive market reception.
AnaptysBio's shares are surging, with a 15.3% intraday increase, currently trading at $67.50 on 0.7x average volume.

Generated by AI

Sentiment

Of the messages about ANAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	90.74% +8.54
Bearish	—	—	0% 0	9.26% -8.54

Bullish· Feb 13

$ANAB is expected to reach $20-$25 in the near future, with potential for significant gains.
The company has seen a substantial bounce of over 45% following a positive data release, indicating strong market momentum.
A significant increase in buying activity has been observed, with multiple large purchases at various price points, suggesting strong investor interest in the asset.

Bearish· Mar 8

AnaptysBio's lead drug, Imsidolimab, failed its first Phase II test, resulting in a significant price drop.
AnaptysBio received a double downgrade from JPMorgan Chase after the trial failure, citing concerns about the company's ability to succeed in a crowded pharmaceutical market.
AnaptysBio's Imsidolimab failed to separate from a placebo in a mid-stage study for a skin blistering disorder, raising questions about the drug's efficacy.

Generated by AI

Topics

Of the messages about ANAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	75%	45.45%	68.49%
Controversies	—	0%	0%	5.96%
Earnings	—	25%	31.82%	2.26%
Analysts	—	0%	11.36%	9.02%
Macro	—	0%	11.36%	0.81%
Technical Analysis	—	0%	0%	13.46%

Earnings· Aug 7

AnaptysBio, Inc. ($ANAB) has beaten EPS loss estimates by $0.10.
$ANAB has reported its Q2 results.
$ANAB's EPS loss estimates have been beaten by $0.10.

Analysts· Feb 11

JP Morgan upgraded AnaptysBio to Overweight from Underweight, with a new price target of $40.
The upgrade led to a significant increase in AnaptysBio's stock price, with a gain of 4.7%.
The positive risk/reward profile of AnaptysBio was cited as a reason for the upgrade.

Announcements· Nov 21

AnaptysBio, Inc. (ANAB) announced a $100 million stock repurchase plan to reinforce financial stability and growth potential.
AnaptysBio and GSK's subsidiary Tesaro are locked in a lawsuit over the Jemperli licensing agreement, with Tesaro seeking to cut royalties and AnaptysBio alleging exclusivity breaches.
The dispute between AnaptysBio and Tesaro has caused ANAB shares to slide 14% in premarket, with a trial set for July 2026.

Generated by AI

Community

Of the messages about ANAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	6.67%	24.63%	52.27%
Newcomers	—	93.33%	75.37%	47.73%

Regulars· Nov 21

AnaptysBio and GSK are engaged in a legal dispute over the Jemperli licensing agreement, with AnaptysBio initiating a counterlawsuit.
The dispute revolves around allegations of a material breach of contract by AnaptysBio, which could potentially result in GSK paying AnaptysBio $60 million and doubling the Jemperli royalty rate.
AnaptysBio has announced a $100 million stock repurchase plan, and the company's stock price has declined by 14.5% due to the ongoing legal dispute with GSK.

Newcomers· Nov 21

$ANAB is a stock to watch in 2026 with several catalysts, having already seen a 199.17% YTD performance.
AnaptysBio is involved in a lawsuit with GSK's Tesaro over Jemperli cancer drug rights, with Tesaro seeking to cut royalties and AnaptysBio alleging exclusivity breaches.
Despite announcing a $100 million buyback, AnaptysBio shares have sold off, with a 7.1% price drop and low participation, suggesting a negative momentum.

Generated by AI

AnaptysBio, Inc. previously reported fourth-quarter and six-month 2026 results showing net income of US$183.88 million for the quarter and US$131 million for the half-year, with basic earnings per share from continuing operations rising to US$6.06 for the quarter and US$6.09 for the six months. A key driver of the very large reported profit was a US$181.5 million income-tax benefit from releasing a deferred-tax valuation allowance following the separation of First Tracks Biotherapeutics, an...

3d agoYahoo Finance

AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?

AnaptysBio, Inc. (NASDAQ:ANAB) reported $176.4 million of income from continuing operations for the six months ended June 30 in results released September 21. A $181.5 million income-tax benefit, primarily from releasing a deferred-tax valuation allowance, turned a $5.1 million pretax loss into that profit. The tax adjustment reflects greater expected use of tax assets following […]

4d agoYahoo Finance

AnaptysBio earnings analysis: questions answered and next catalysts

7d agoInvesting.com

Why is AnaptysBio stock rising afterhours today?

8d agoInvesting.com

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

8d agoYahoo Finance

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the l

8d agoYahoo Finance

Also Discussed

Investors talking about ANAB also mention

#	Name	Attention
1	DBV Technologies S.A. Sponsored ADRDBVT	0%0
2	BPMC - Blueprint Medicines Corporation	——
3	Neurocrine Biosciences, Inc.NBIX	0%new
4	JNCE - Jounce Therapeutics, Inc.	——
5	Theravance Biopharma Inc.TBPH	0%new
6	MRUS - Merus N.V.	——
7	Nurix Therapeutics, Inc.NRIX	0%new
8	Heron Therapeutics, Inc.HRTX	0%+0
9	Alumis Inc.ALMS	0%0
10	IGMS - IGM Biosciences, Inc.	——

AnaptysBio, Inc.

Healthcare
Biotechnology

AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as well as royalty and collaboration assets. Its portfolio includes investigational therapies aimed at conditions such as rheumatoid arthritis, ulcerative colitis, atopic dermatitis, celiac disease, eosinophilic esophagitis, and generalized pustular psoriasis. The company also manages financial collaborations tied to partnered assets, reflecting a business model that combines internal drug development with externally partnered programs. Based in San Diego, California, AnaptysBio plays a role in the biotechnology market as a specialist in immune cell modulation and antibody therapeutics.

Website

Location

10770 Wateridge Circle

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about ANAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Apr 27

AnaptysBio's shares are trading higher after a Delaware Chancery Court ruled in favor of the company in a breach of contract claim, leaving current royalty rates intact.
The company's restructuring into a royalty management firm, following the spin-off of First Tracks Biotherapeutics, has received a positive market reception.
AnaptysBio's shares are surging, with a 15.3% intraday increase, currently trading at $67.50 on 0.7x average volume.

Generated by AI

Sentiment

Of the messages about ANAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	90.74% +8.54
Bearish	—	—	0% 0	9.26% -8.54

Bullish· Feb 13

$ANAB is expected to reach $20-$25 in the near future, with potential for significant gains.
The company has seen a substantial bounce of over 45% following a positive data release, indicating strong market momentum.
A significant increase in buying activity has been observed, with multiple large purchases at various price points, suggesting strong investor interest in the asset.

Bearish· Mar 8

AnaptysBio's lead drug, Imsidolimab, failed its first Phase II test, resulting in a significant price drop.
AnaptysBio received a double downgrade from JPMorgan Chase after the trial failure, citing concerns about the company's ability to succeed in a crowded pharmaceutical market.
AnaptysBio's Imsidolimab failed to separate from a placebo in a mid-stage study for a skin blistering disorder, raising questions about the drug's efficacy.

Generated by AI

Topics

Of the messages about ANAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	75%	45.45%	68.49%
Controversies	—	0%	0%	5.96%
Earnings	—	25%	31.82%	2.26%
Analysts	—	0%	11.36%	9.02%
Macro	—	0%	11.36%	0.81%
Technical Analysis	—	0%	0%	13.46%

Earnings· Aug 7

AnaptysBio, Inc. ($ANAB) has beaten EPS loss estimates by $0.10.
$ANAB has reported its Q2 results.
$ANAB's EPS loss estimates have been beaten by $0.10.

Analysts· Feb 11

JP Morgan upgraded AnaptysBio to Overweight from Underweight, with a new price target of $40.
The upgrade led to a significant increase in AnaptysBio's stock price, with a gain of 4.7%.
The positive risk/reward profile of AnaptysBio was cited as a reason for the upgrade.

Announcements· Nov 21

AnaptysBio, Inc. (ANAB) announced a $100 million stock repurchase plan to reinforce financial stability and growth potential.
AnaptysBio and GSK's subsidiary Tesaro are locked in a lawsuit over the Jemperli licensing agreement, with Tesaro seeking to cut royalties and AnaptysBio alleging exclusivity breaches.
The dispute between AnaptysBio and Tesaro has caused ANAB shares to slide 14% in premarket, with a trial set for July 2026.

Generated by AI

Community

Of the messages about ANAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	6.67%	24.63%	52.27%
Newcomers	—	93.33%	75.37%	47.73%

Regulars· Nov 21

AnaptysBio and GSK are engaged in a legal dispute over the Jemperli licensing agreement, with AnaptysBio initiating a counterlawsuit.
The dispute revolves around allegations of a material breach of contract by AnaptysBio, which could potentially result in GSK paying AnaptysBio $60 million and doubling the Jemperli royalty rate.
AnaptysBio has announced a $100 million stock repurchase plan, and the company's stock price has declined by 14.5% due to the ongoing legal dispute with GSK.

Newcomers· Nov 21

$ANAB is a stock to watch in 2026 with several catalysts, having already seen a 199.17% YTD performance.
AnaptysBio is involved in a lawsuit with GSK's Tesaro over Jemperli cancer drug rights, with Tesaro seeking to cut royalties and AnaptysBio alleging exclusivity breaches.
Despite announcing a $100 million buyback, AnaptysBio shares have sold off, with a 7.1% price drop and low participation, suggesting a negative momentum.

Generated by AI

AnaptysBio

Social

Apr 27

Bullish· Feb 13

Bearish· Mar 8

Earnings· Aug 7

Analysts· Feb 11

Announcements· Nov 21

Regulars· Nov 21

Newcomers· Nov 21

AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance

AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?

AnaptysBio earnings analysis: questions answered and next catalysts

Why is AnaptysBio stock rising afterhours today?

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

Also Discussed

AnaptysBio, Inc.

Company Information

Location

AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance

AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?

AnaptysBio earnings analysis: questions answered and next catalysts

Why is AnaptysBio stock rising afterhours today?

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

Also Discussed

Social

Apr 27

Bullish· Feb 13

Bearish· Mar 8

Earnings· Aug 7

Analysts· Feb 11

Announcements· Nov 21

Regulars· Nov 21

Newcomers· Nov 21